TriCipher Joins Partner Program
TriCipher today joined the SAFE (Signatures and Authentication for Everyone) BioPharma Association Vendor Partner Program
CAMBRIDGE, U.K. -- TriCipher today joined the SAFE(tm) (Signatures and Authentication for Everyone) BioPharma Association Vendor Partner Program, pledging to promote the adoption of the SAFE standards through the company's user and transaction authentication solutions. SAFE-approved credentials will seamlessly operate on TriCipher Armored Credential System (TACS), the company's strong authentication platform leveraging a variety of multi-factor credentials.
The industry group gives TriCipher access to forward-thinking corporate users of digital information processing, such as Amgen, AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. By agreeing to credentialing standards, these companies reduce the cost and time for pharmaceutical companies to advance drug development and deploy new business processes.
SAFE provides the industry's legal foundation for digital signatures and user authentication across pharmaceutical companies. Its standards are legally enforceable because they ensure user authentication, digital document integrity and auditable non-repudiation of users' actions.
"The pharmaceutical industry sets the bar for other industries with highly regulated and valuable online activities," said John De Santis, TriCipher's CEO. "SAFE and TriCipher make it possible to get more business value out of strong authentication credentials, increasing profits and better serving customers with faster product development and lower costs."
About the Author
You May Also Like
DevSecOps/AWS
Oct 17, 2024Social Engineering: New Tricks, New Threats, New Defenses
Oct 23, 202410 Emerging Vulnerabilities Every Enterprise Should Know
Oct 30, 2024Simplify Data Security with Automation
Oct 31, 2024